Roche Reports CE Label Expansion Of VENTANA PD-L1 Assay In Non-small Cell Lung Cancer

Roche (RHHBY) announced CE label expansion of the VENTANA PD-L1 (SP263) Assay in non-small cell lung cancer or NSCLC as a companion diagnostic for Tecentriq (atezolizumab).

The current standard of care for patients with early stage lung cancer is removal of the tumour, which may be followed by chemotherapy. But about half of these patients will have their cancer return following surgery.

The VENTANA PD-L1 (SP263) Assay helps determine which patients with non-small cell lung cancer may benefit from treatment with Tecentriq immunotherapy. It potentially reduces their risk of disease recurrence or death by more than half.

The European Commission approved Tecentriq in June 2022 as adjuvant treatment following surgery and platinum-based chemotherapy for adults whose Stage II-IIIA NSCLC tumours have high PD-L1 protein expression.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Lidl US has recalled its 8.4 oz Favorina branded Advent Calendar, i.e., Premium Chocolate with a Creamy Filling, citing potential Salmonella contamination, the U.S. Food and Drug Administration said. The products were available for sale at Lidl stores between October 12, 2022 and December 5, 2022. They will have a BEST IF USED BY year of 2023, and barcode number of 4056489516965. Vaccine partners Pfizer Inc. and BioNTech SE are seeking emergency use authorization or EUA from the U.S. Food and Drug Administration to offer their bivalent COVID-19 vaccine to children 6 months through 4 years of age. If authorized, the vaccine would be part of a primary series for children in this age group. Kraft Heinz Foods Co. is recalling around 2,400 pounds of ready-to-eat or RTE ham and cheese loaf products citing possible cross-contamination with under-processed products, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced.
Follow RTT